JNK-IN-8

News alerts, weekly reports and conference planners

Company:

Dana-Farber Cancer Institute, University of North Carolina-Chapel Hill

Drug class:

JNK inhibitor

Related drugs:

‹

›

CCL2 elevation	Triple Negative Breast Cancer	CCL2 elevation	Triple Negative Breast Cancer	JNK-IN-8 Resistant: D – Preclinical JNK-IN-8 Resistant : D	JNK-IN-8 Resistant: D – Preclinical JNK-IN-8 Resistant : D
BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	BCR-ABL1 fusion	B Acute Lymphoblastic Leukemia	dasatinib + JNK-IN-8 Sensitive: D – Preclinical dasatinib + JNK-IN-8 Sensitive : D	dasatinib + JNK-IN-8 Sensitive: D – Preclinical dasatinib + JNK-IN-8 Sensitive : D

Associations
(2)